Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Neoplasms 7Ovarian Neoplasms 6Colorectal Neoplasms 4Prostatic Neoplasms 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Recurrence 2Peritoneal Neoplasms 2Lung Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Radiation Pneumonitis 1Patients With Any Advanced Solid Tumors 1Ovarian Diseases 1Oligodendroglioma 1Neuroendocrine Tumors 1Neoplasms by Site 1Mesothelioma, Malignant 1Melanoma, Cutaneous Malignant 1Malignant Solid Tumour 1Lymphangioleiomyomatosis 1Leukemia, Myeloid, Acute 1

Interventions

Carboplatin 69Paclitaxel 63Cisplatin 32Topotecan 29Gemcitabine 21Docetaxel 20Cyclophosphamide 18Filgrastim 17liposomal doxorubicin 15Peripheral Blood Stem Cell Transplantation 15Bevacizumab 14sargramostim 11Taxes 10Drug Therapy 10Therapeutics 7Psychiatric Rehabilitation 7Immunohistochemistry 7Erlotinib Hydrochloride 7Amifostine 7Melphalan 6Chemotherapy, Adjuvant 6rucaparib 5pembrolizumab 5mirvetuximab soravtansine 5ixabepilone 5Surgical Procedures, Operative 5Mass Spectrometry 5Interleukin-12 Subunit p35 5Flow Cytometry 5Etoposide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Ovarian Epithelial × nintedanib × Clear all
NCT01669798 2018-10-16

BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer

Duke University

Phase 2 Completed
32 enrolled 19 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡